Abstract
Prostate cancer develops from clones that are already present as early as thirty-five years of age, when circulating concentrations of androgens are high. The progression of the disease is low and the cancer is diagnosed at a more advanced age. Prostate cancer evolves from an androgen dependant stage to stage where it escapes from all antiandrogenic treatments. The patient usually dies within two years following the diagnosis of advanced cancer. Therefore, it is of great interest to develop new therapies for androgen independent prostate cancer. The androgen independent evolution of prostate cancer is a complex phenomenon at the cellular and molecular levels. It includes an increased sensitivity to growth factors, the control of proliferation pathways, apoptotic and survival pathways as well as the control of angiogenesis. Epidemiological studies have also suggested that certain vitamins or phyto-oestrogens could protect against prostate cancer development. The present review attempts to present an overview of the fundamental research in cellular signalling which could be interesting as target for the treatment of androgen independent prostate cancer. Also the potential interest of non-androgenic steroids was reviewed for the same goal.
Keywords: prostate, cancer, androgen, genes, molecular therapy
Current Pharmaceutical Design
Title: New Features in the Treatment of Androgen-Independent Prostate Cancer
Volume: 10 Issue: 5
Author(s): Jean Closset, Hayet Ammar, Viet-Ha Nguyen, Anne Cornet and Eric Reiter
Affiliation:
Keywords: prostate, cancer, androgen, genes, molecular therapy
Abstract: Prostate cancer develops from clones that are already present as early as thirty-five years of age, when circulating concentrations of androgens are high. The progression of the disease is low and the cancer is diagnosed at a more advanced age. Prostate cancer evolves from an androgen dependant stage to stage where it escapes from all antiandrogenic treatments. The patient usually dies within two years following the diagnosis of advanced cancer. Therefore, it is of great interest to develop new therapies for androgen independent prostate cancer. The androgen independent evolution of prostate cancer is a complex phenomenon at the cellular and molecular levels. It includes an increased sensitivity to growth factors, the control of proliferation pathways, apoptotic and survival pathways as well as the control of angiogenesis. Epidemiological studies have also suggested that certain vitamins or phyto-oestrogens could protect against prostate cancer development. The present review attempts to present an overview of the fundamental research in cellular signalling which could be interesting as target for the treatment of androgen independent prostate cancer. Also the potential interest of non-androgenic steroids was reviewed for the same goal.
Export Options
About this article
Cite this article as:
Closset Jean, Ammar Hayet, Nguyen Viet-Ha, Cornet Anne and Reiter Eric, New Features in the Treatment of Androgen-Independent Prostate Cancer, Current Pharmaceutical Design 2004; 10 (5) . https://dx.doi.org/10.2174/1381612043453216
DOI https://dx.doi.org/10.2174/1381612043453216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Taxane Induced Cystoid Macular Edema: Case Report and Integrated Pathogenic Theory
Current Drug Safety Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Hapten Recognition by T Cells: A Functional and Molecular View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Design, Synthesis, Molecular Docking and Biological Evaluation of 1-(benzo[d]thiazol-2-ylamino)(phenyl)methyl)naphthalen-2-ol Derivatives as Antiproliferative Agents
Letters in Organic Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry PNP Anticancer Gene Therapy
Current Topics in Medicinal Chemistry Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Editorial
Current Molecular Medicine Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Cell Penetrating Peptides and the Mechanisms for Intracellular Entry
Current Pharmaceutical Biotechnology A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Current Cancer Drug Targets Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Synthesis and Biochemical Evaluation of a Range of 4-(n-alkanesulfonate) benzyl Imidazole-Based Compounds as Inhibitors of Rat Testicular 17α-hydroxylase/17,20-lyase (P450<sub>17α</sub>) in the Treatment of Hormone- Dependent Prostate Cancer
Letters in Drug Design & Discovery Pharmacokinetics and Disposition of Various Drug Loaded Biodegradable Poly(Lactide-Co-Glycolide) (PLGA) Nanoparticles
Current Drug Metabolism MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Machine Learning-Based Virtual Screening Strategy RevealsSome Natural Compounds as Potential PAK4 Inhibitors in Triple Negative Breast Cancer
Current Proteomics